The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...
Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...
GlobalData on MSN17h
Takeda announces appointment of Julie Kim as CEOTakeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and ...
Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...
Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the ...
India], January 31: Zydus Takeda Healthcare Private Limited (ZTHPL), a joint venture company set up by Zydus Lifesciences ...
Concurrently, the company also announced the decision to appoint Julie Kim as the Chief Executive Officer, succeeding Christophe Weber, who plans to retire from the position in June 2026. Kim ...
Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback